03:56 , May 12, 2017 |  BC Week In Review  |  Financial News

Aadi raises $23M in series A

On May 8, cancer company Aadi Bioscience Inc. (Pacific Palisades, Calif.) raised $23 million in a series A round led by Hermed Capital. Celgene Corp. (NASDAQ:CELG), Vivo Capital, Decheng Capital, Helsinn Investment Fund and Star...
20:12 , May 8, 2017 |  BC Extra  |  Financial News

Aadi raises $23M series A round

Aadi Bioscience Inc. (Pacific Palisades, Calif.) raised $23 million in a series A led by Hermed Capital. Also participating were Celgene Corp. (NASDAQ:CELG), Vivo Capital, Decheng Capital, Helsinn Investment Fund and Star Summit Ventures. Aadi...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Nab-rapamycin: Phase II started

AADi began an open-label, U.S. pivotal Phase II trial to evaluate ABI-009 in about 35 patients. AADi has exclusive, worldwide rights to develop and commercialize ABI-009 from Celgene (see BioCentury, May 26, 2014). AADi LLC...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) was up €0.29 to €11.32 on Friday after EMA's CHMP reiterated its recommendation against conditional approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

AADi, Celgene deal

Celgene granted AADi an exclusive, worldwide license to develop and commercialize Celgene's ABI-009 , a nanoparticle albumin-bound (nab) formulation of rapamycin, also known as sirolimus. Financial terms are not disclosed. AADi founder, President and CEO...
00:43 , May 21, 2014 |  BC Extra  |  Company News

Celgene licenses nab-rapamycin to AADi

Celgene Corp. (NASDAQ:CELG) granted AADi LLC (Pacific Palisades, Calif.) an exclusive, worldwide license to develop and commercialize Celgene's ABI-009 , a nanoparticle albumin-bound (nab) formulation of rapamycin, also known as sirolimus. Financial terms are not...